Prognostic Value of Serum Galectin-3 for Survival in Patients with Cardiac Light-Chain Amyloidosis
Journal of Cardiovascular Development and Disease · 29.06.2024 · 11 (7) · 202
DOI: 10.3390/jcdd11070202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 29.06.2024. Verfasst von Xinglin Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National High Level Hospital Clinical Research Funding, Xiong'an New Area Science and Technology Innovation Special Project.
Abstract (Originalsprache)
Background
Amyloid light-chain (AL) amyloidosis is a multisystem disorder, with cardiac amyloid infiltration being a prevalent manifestation. This study aimed to explore the prognostic value of galectin-3 (Gal-3), a soluble marker associated with fibrosis, inflammation, heart failure, and kidney injury, in patients with cardiac AL amyloidosis.
Methods
A total of 60 patients who were diagnosed with cardiac AL amyloidosis from January 2015 to May 2018 were enrolled. The prognostic value of Gal-3 was assessed. Receiver operating characteristic (ROC) curves were used to evaluate the predictive accuracy of Gal-3. A Gal-3 cut-off value was identified to predict survival rates.
Results
The ROC curves demonstrated a moderate predictive accuracy of Gal-3 for 0.5- and 5-year survival, with area under the curve (AUC) values of 0.722 and 0.788, respectively. A Gal-3 cut-off value of 15.154 ng/mL was found to predict survival. Kaplan–Meier survival analysis revealed a significant difference in mean overall survival between patients with Gal-3 levels below and above the established cut-off (69.2 months versus 42.1 months, respectively; p = 0.036). Multivariate analysis confirmed that Gal-3 > 15.154 ng/mL remained an independent predictor of survival (HR 2.451, 95% CI 1.017–5.910, p = 0.046).
Conclusions
This study suggests that Gal-3 holds independent prognostic value for survival in patients with cardiac AL amyloidosis. Gal-3 could potentially enhance the prognostic capabilities of the current soluble markers, thereby improving the management of cardiac AL amyloidosis. However, further validation in larger prospective studies is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
ORCID-Profile: Jinghong Zhang
Förderung
- National Key Research and Development Program of China
- National High Level Hospital Clinical Research Funding
- Xiong'an New Area Science and Technology Innovation Special Project
- National High-Level Hospital Clinical Research Funding
- Xiong’an New Area Science and Technology Innovation Special Project
Zitieren
APA
Yang, X., Huang, J., Zhang, J., Li, J., & Tian, Z. (2024). Prognostic Value of Serum Galectin-3 for Survival in Patients with Cardiac Light-Chain Amyloidosis. Journal of Cardiovascular Development and Disease, 11(7), 202. https://doi.org/10.3390/jcdd11070202
Vancouver
Yang X, Huang J, Zhang J, Li J, Tian Z. Prognostic Value of Serum Galectin-3 for Survival in Patients with Cardiac Light-Chain Amyloidosis. Journal of Cardiovascular Development and Disease. 2024;11(7):202. doi:10.3390/jcdd11070202
BibTeX
@article{Yang2024,
author = {Yang, Xinglin and Huang, Jin and Zhang, Jinghong and Li, Jian and Tian, Zhuang},
title = {Prognostic Value of Serum Galectin-3 for Survival in Patients with Cardiac Light-Chain Amyloidosis},
journal = {Journal of Cardiovascular Development and Disease},
year = {2024},
volume = {11},
number = {7},
pages = {202},
doi = {10.3390/jcdd11070202}
}
EUVIMED